After screening out HR-proficient breast cancer cell lines, the gene panel accurately predicted the cellular sensitivity of these cell lines to PARP inhibitor/cisplatin (Supplementary Fig. S14b, lower panel). This evidence concerns the gene PARP1 and breast cancer.